- Home
- CANF vs OP Comparison
CANF vs OP Comparison
Compare CANF & OP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- OP
- Stock Information
- Founded
- CANF 1994
- OP 2021
- Country
- CANF Israel
- OP Greece
- Employees
- CANF N/A
- OP N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- OP
- Sector
- CANF Health Care
- OP
- Exchange
- CANF Nasdaq
- OP Nasdaq
- Market Cap
- CANF 13.5M
- OP 14.3M
- IPO Year
- CANF N/A
- OP N/A
- Fundamental
- Price
- CANF $0.66
- OP $0.12
- Analyst Decision
- CANF Strong Buy
- OP
- Analyst Count
- CANF 2
- OP 0
- Target Price
- CANF $14.00
- OP N/A
- AVG Volume (30 Days)
- CANF 314.0K
- OP 49.1M
- Earning Date
- CANF 08-29-2025
- OP 08-12-2025
- Dividend Yield
- CANF N/A
- OP N/A
- EPS Growth
- CANF N/A
- OP N/A
- EPS
- CANF N/A
- OP N/A
- Revenue
- CANF $674,000.00
- OP $25,702,000.00
- Revenue This Year
- CANF $461.72
- OP N/A
- Revenue Next Year
- CANF N/A
- OP N/A
- P/E Ratio
- CANF N/A
- OP N/A
- Revenue Growth
- CANF N/A
- OP 35.58
- 52 Week Low
- CANF $0.63
- OP $0.11
- 52 Week High
- CANF $3.24
- OP $3.17
- Technical
- Relative Strength Index (RSI)
- CANF 12.02
- OP 33.20
- Support Level
- CANF $1.00
- OP $0.14
- Resistance Level
- CANF $1.05
- OP $0.22
- Average True Range (ATR)
- CANF 0.05
- OP 0.20
- MACD
- CANF -0.04
- OP -0.11
- Stochastic Oscillator
- CANF 5.86
- OP 0.41
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.